Medherant has an exclusive worldwide licence to a novel, revolutionary, pressure sensitive adhesive developed by Bostik. The drug to be delivered is mixed with the adhesive.
Medherant is developing its own TEPI Patch products which is intends to license for commercialisation. Phase I clinical studies with the first product have shown that the novel adhesive is well-tolerated. Medherant is also collaborating with third parties to formulate their drugs for transdermal delivery and expects to receive its first licence revenues in 2019.
Medherant has secured funding from Mercia Fund Management and private investors.